ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
6 announcements with these filters
Zydus Lifesciences announced that a recent USFDA inspection of its pharmacovigilance and post-marketing surveillance system at the company’s USA office concluded with nil observations.
CRISIL reaffirmed Zydus Lifesciences ratings: CRISIL AAA/Stable (LT) and A1+ (ST) on a Rs.4,724 Cr bank facility, plus CPs and NCDs. The stable outlook signals unchanged strong credit standing.
Zydus Lifesciences' subsidiary, ZPUI, settled an antitrust litigation case for a total payment of USD 5.9 million, without admission of wrongdoing.
Zydus delivered robust FY27 Q1 results driven by strong India-branded formulations and U.S. generic resilience.
Zydus Lifesciences reported strong Q1 FY27 revenue growth of 22% YoY, driven by robust performance in India and International formulations, despite a decline in PAT and EBITDA margins.
Zydus Lifesciences Ltd reported revenue from operations of ₹8,017 Cr (+22.0% YoY) and net profit of ₹939.8 Cr (-35.9% YoY) for Q1 FY27.